Blue Earth Diagnostics

Blue Earth Diagnostics is a commercial-stage, private diagnostics company specializing in targeted radiopharmaceuticals for cancer imaging. It leverages a proven track record in rapid development and commercialization to bring novel PET imaging agents to market, aiming to transform clinical decision-making in oncology. As part of the Bracco family, it benefits from global commercial infrastructure and expertise, with a pipeline focused on expanding into new cancer indications. The company's strategy centers on applying its molecular imaging knowledge to drive future therapeutic advancements.

Development and commercialization of targeted positron emission tomography (PET) radiopharmaceuticals for cancer imaging, focusing on biomarkers like PSMA and amino acid transporters.

The company competes in the molecular imaging diagnostics market against large players like GE HealthCare, Siemens Healthineers, and Lantheus Holdings (with Pylarify), as well as other specialized radiopharmaceutical companies. Its differentiation lies in its focused expertise, agile development, and strategic backing from Bracco.